Our mission
Providing custom tailored, high quality preclinical services to prime your drugs for success.
We offer expert solutions for optimal preclinical testing
Biomedcode scientists coauthor two publications, one in Annals of Rheumatic diseases and one in JCI insight, showing that Tg197 and TNFΔΑRΕ mice develop heart valve pathology sharing common mesenchymal cell-specific aetiopathogenic mechanisms with arthritis.
Biomedcode's human TNF transgenic arthritis model, (Tg197), contributes to the non-clinical assessment of adalimumab biosimilar GP2017 with originator Humira.
Biomedcode is pleased to announce that it has received national funding from the General Secretary for Research and Technology supporting the innovative research networks HUPLA and BreasCaRANKL that combine the efforts of industrial and renowned academic partners to develop precision drug evaluation tools for the preclinical development of novel therapies for Multiple Sclerosis and Breast Cancer.
OUR CLIENTS SAY
"Our company had a pleasant experience of productive collaboration with Biomedcode s.a. in 2015. We would like to especially highlight the high quality of the study protocol preparation and report writing as well as efficient communication with Biomedcode’s CEO. We greatly appreciate your professionalism and looking forward to our future collaboration."
"We have several collaborations with Biomedcode, their scientific and efficient experiment schedules made each collaboration accomplished according to plan. From Biomedcode, we obtained convincing study reports and detailed records, which saved a lot of time for us in whole pre-clinical stage. We believe contracting professional works to such a professional and sophisticated group is a wise choice."
"It was a great pleasure working with Biomedcode that exhibited great expertise in preclinical testing and handled all the steps of the study with great professionalism always abiding by the terms of the agreement and always staying in close communication with us making this a very productive collaboration."
Clients
Biomedcode scientists coauthor a publication in Annals of Rheumatic diseases showing that Tg197 mice develop heart valve pathology sharing common...
Biomedcode scientists coauthor a publication in JCI insight showing that TNFΔARE mice develop mesenchymal cell dependent heart valve pathology with...
Biomedcode's human TNF transgenic arthritis model, (Tg197), contributes to the non-clinical assessment of etanercept biosimilar GP2015 with...